First Launch For Osteoporosis Drug

Ono Pharmaceutical and Astellas Pharma have launched the new molecular entity (NME) Recalbon/Bonoteo (minodronic acid) in Japan for the treatment of osteoporosis. The development is significant because it endorses the Asian country's increasingly maligned R&D sector. However, BMI cautions that the product will face significant competition from established

To read the full article, please choose one of the following options: